

Supplementary Materials

Table S1. Specific primer sequence of Real-time RT-PCR.

Genes	Primers
IL-6	Forward: 5'- AGACAGCCACTCACCTCTTCAG Reverse: 5'- TTCTGCCAGTGCCTCTTTGCTG
ChIP and Re-ChIP IL-6	Forward: 5'-GTTGTGTCTTGCGATGCTAAAG Reverse: 5'-GCTTCTCTTTTCGTTCCCGTG
CD44	Forward: 5'-AGAAGGTGTGGGCAGAAGAA-3' Reverse: 5'-AAATGCACCATTTCTGAGA-3'
Nanog	Forward: 5'-ATGCCTCACACGGAGACTGT-3' Reverse: 5'-AAGTGGGTTGTTTGCCTTTG-3'
C-myc	Forward: 5'-AATGAAAAGGCCCCCAAGGTAGTTATCC-3' Reverse : 5'-AGCAAACCCGGAGGAGT-3'
Sox2	Forward : 5'-TTGCTGCCTCTTTAAGACTAGGA-3' Reverse : 5'-CTGGGGCTCAAACCTCTCTC-3'
Oct4	Forward: 5'-AGCAAACCCGGAGGAGT-3'-3' Reverse: 5'-CCACATCGGCCTGTGTATATC-3'
β -actin	Forward: 5'-TGTTACCAACTGGGACGACA-3' Reverse : 5'-GGGGTGTGAAGGTCTCAA-3'




Figure S1. Correlation of Stat3/IL-6 and PAK1/IL6 in breast invasive carcinoma, breast cancer ER-&HER2+, and lymphoid neoplasm diffuse large B-cell lymphoma. Breast invasive carcinoma showed no correlation of IL-6/Stat3 and IL-6/PAK1. Breast cancer ER-&HER2+ showed that correlation of IL-6/pStat3 is 0.73. Lymphoid neoplasm diffuse large B-cell lymphoma showed that: correlation of IL-6/Stat3 and IL-6/PAK1 were 0.58 and 0.52.




Figure 1A




Figure 1C




Figure 2G




Figure 2J




Figure 3B




Figure 3CD

B




Figure 4B

E




Figure 4E




Figure 4F




Figure 5C




Figure 5C




Figure 6B




Figure 6B




Figure 7E

Figure S2. Western blot figures including densitometry readings/intensity ratio of each band, the whole blot, and all the bands with all molecular weight markers on the Western blot.